Lung Cancer Diagnostic
Lung Cancer
ResearchActive
Key Facts
About Owlstone Medical
Owlstone Medical is the recognized leader in breath-based VOC biomarker research and diagnostic test development. Its core Breath Biopsy® platform enables the reliable collection and analysis of breath samples, offering a completely non-invasive window into systemic health for early disease detection and treatment monitoring. The company operates a dual business model, providing research products and services to partners while advancing its own pipeline of diagnostic tests, supported by significant non-dilutive funding and venture investment. Its vision is to become the global standard in breath analysis, with active programs targeting multi-cancer early detection and specific conditions like cystic fibrosis.
View full company profileOther Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| OncoStrong™ | Lamark Biotech | Preclinical |
| 15dPMJ2 | Claradele Pharmaceuticals | Research |
| SUPLEXA | Alloplex Biotherapeutics | Phase 1 |
| Oncology Digital Biomarkers | Imvaria | Development |
| Aerosolized Platinum Nanoparticles | HylaPharm | Pre-clinical |
| ENV105 | Kairos Pharma | Phase 1 |
| AI for Lung Cancer | Invenio Imaging | Research |
| Liposome Program | NanoTech Pharma | Preclinical/Phase 1/2 |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| AI Biomarkers for Lung Cancer | BioAI Health | Unknown |
| PRDM2 Target | ARIZ Precision Medicine | Preclinical |
| ZEN-3694 | Zenith Epigenetics | Proof-of-Concept |